Literature DB >> 16397025

Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection.

Thierry Soussi1, Bernard Asselain, Dalil Hamroun, Shunsuke Kato, Chikashi Ishioka, Mireille Claustres, Christophe Béroud.   

Abstract

PURPOSE: Analyses of the pattern of p53 mutations have been essential for epidemiologic studies linking carcinogen exposure and cancer. We were concerned by the inclusion of dubious reports in the p53 databases that could lead to controversial analysis prejudicial to the scientific community. EXPERIMENTAL
DESIGN: We used the universal mutation database p53 database (21,717 mutations) combined with a new p53 mutant activity database (2,300 mutants) to perform functional analysis of 1,992 publications reporting p53 alterations. This analysis was done using a statistical approach similar to that of clinical meta-analyses.
RESULTS: This analysis reveals that some reports of infrequent mutations are associated with almost normal activities of p53 proteins. These particular mutations are frequently found in studies reporting multiple mutations in one tumor, silent mutations, or lacking mutation hotspots. These reports are often associated with particular methodologies, such as nested PCR, for which key controls are not satisfactory.
CONCLUSIONS: We show the importance of accurate functional analysis before inferring any genetic variation. The quality of the p53 databases is essential in order to prevent erroneous analysis and/or conclusions. The availability of functional data from our new p53 web site (http://p53.free.fr and http://www.umd.be:2072/) will allow functional prescreening to identify potential artifactual data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397025     DOI: 10.1158/1078-0432.CCR-05-0413

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors.

Authors:  Karolina Edlund; Ola Larsson; Adam Ameur; Ignas Bunikis; Ulf Gyllensten; Bernard Leroy; Magnus Sundström; Patrick Micke; Johan Botling; Thierry Soussi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-24       Impact factor: 11.205

2.  CLCA2 as a p53-inducible senescence mediator.

Authors:  Chizu Tanikawa; Hidewaki Nakagawa; Yoichi Furukawa; Yusuke Nakamura; Koichi Matsuda
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

3.  Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer.

Authors:  Yizeng Yang; Hiroshi Nakagawa; Marie-Pier Tetreault; Janelle Billig; Noel Victor; Abha Goyal; Antonia R Sepulveda; Jonathan P Katz
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

4.  p53 mutation alters the effect of the esophageal tumor suppressor KLF5 on keratinocyte proliferation.

Authors:  Yizeng Yang; Rohinton S Tarapore; Melissa H Jarmel; Marie-Pier Tetreault; Jonathan P Katz
Journal:  Cell Cycle       Date:  2012-09-18       Impact factor: 4.534

5.  A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion.

Authors:  Katharine D Grugan; Maria E Vega; Gabrielle S Wong; J Alan Diehl; Adam J Bass; Kwok K Wong; Hiroshi Nakagawa; Anil K Rustgi
Journal:  Cancer Biol Ther       Date:  2013-06-18       Impact factor: 4.742

6.  Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.

Authors:  Laurence Lodé; Marion Eveillard; Valérie Trichet; Thierry Soussi; Soraya Wuillème; Steven Richebourg; Florence Magrangeas; Norbert Ifrah; Loïc Campion; Catherine Traullé; François Guilhot; Denis Caillot; Gérald Marit; Claire Mathiot; Thierry Facon; Michel Attal; Jean-Luc Harousseau; Philippe Moreau; Stéphane Minvielle; Hervé Avet-Loiseau
Journal:  Haematologica       Date:  2010-07-15       Impact factor: 9.941

Review 7.  Applications of computational algorithm tools to identify functional SNPs.

Authors:  C George Priya Doss; C Sudandiradoss; R Rajasekaran; Parikshit Choudhury; Priyanka Sinha; Pragnya Hota; Udit Prakash Batra; Sethumadhavan Rao
Journal:  Funct Integr Genomics       Date:  2008-06-19       Impact factor: 3.410

8.  Regulation of histone modification and chromatin structure by the p53-PADI4 pathway.

Authors:  Chizu Tanikawa; Martha Espinosa; Akari Suzuki; Ken Masuda; Kazuhiko Yamamoto; Eiju Tsuchiya; Koji Ueda; Yataro Daigo; Yusuke Nakamura; Koichi Matsuda
Journal:  Nat Commun       Date:  2012-02-14       Impact factor: 14.919

9.  Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers.

Authors:  Simone Hettmer; Natasha M Archer; Gino R Somers; Ana Novokmet; Amy J Wagers; Lisa Diller; Carlos Rodriguez-Galindo; Lisa A Teot; David Malkin
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

10.  The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Authors:  Paulina M Wojnarowicz; Kathleen Klein Oros; Michael C J Quinn; Suzanna L Arcand; Karen Gambaro; Jason Madore; Ashley H Birch; Manon de Ladurantaye; Kurosh Rahimi; Diane M Provencher; Anne-Marie Mes-Masson; Celia M T Greenwood; Patricia N Tonin
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.